Panacea Biotec Limited (NSE:PANACEABIO)

Panacea Biotec Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	1,070	471.74	398.52	503.5	520.79
Short-Term Investments	31.5	687.57	1,598	4,963	390.99
Trading Asset Securities	-	403.62	134.16	50.01	-
Cash & Short-Term Investments	1,101	1,563	2,130	5,516	911.78
Cash Growth	-29.54%	-26.64%	-61.38%	505.00%	74.95%
Accounts Receivable	725.6	574.19	600.92	816.56	846.84
Other Receivables	-	10.57	12.02	10.58	63.42
Receivables	751.3	616.58	628.74	841.54	930.21
Inventory	2,137	1,779	2,021	2,127	1,741
Prepaid Expenses	-	60.63	52.2	53.49	52.87
Other Current Assets	1,463	832.28	850.84	1,367	1,473
Total Current Assets	5,452	4,852	5,683	9,906	5,110
Property, Plant & Equipment	6,369	6,348	6,163	6,255	6,279
Long-Term Investments	0.7	1.68	1.74	803.91	5.52
Other Intangible Assets	422.6	276.32	153.3	132.36	139.71
Long-Term Deferred Tax Assets	-	-	-	237.51	1.47
Long-Term Deferred Charges	-	83.66	106.11	5.88	12.5
Other Long-Term Assets	653.4	844.87	600.99	248.48	227.46
Total Assets	12,898	12,407	12,712	17,589	11,775
Accounts Payable	2,258	1,537	1,773	2,347	2,467
Accrued Expenses	363.5	356.88	361.43	404.63	381.76
Short-Term Debt	-	-	0.55	-	-
Current Portion of Long-Term Debt	-	-	-	0.52	844.46
Current Income Taxes Payable	0.1	1.35	5.6	0.85	0.26
Current Unearned Revenue	-	171.03	196.62	-	-
Other Current Liabilities	1,049	1,022	980.88	5,010	797.87
Total Current Liabilities	3,670	3,088	3,318	7,764	4,491
Long-Term Debt	222.1	209.94	201.64	341.03	7,351
Long-Term Unearned Revenue	108.5	218.46	321.39	455.88	29.06
Long-Term Deferred Tax Liabilities	232.8	225.45	203.71	-	-
Other Long-Term Liabilities	358	117.78	131.22	147.3	2,049
Total Liabilities	4,591	4,024	4,311	8,852	14,092
Common Stock	61.3	61.25	61.25	61.25	61.25
Additional Paid-In Capital	-	919.4	919.4	919.4	919.4
Retained Earnings	-	8,678	8,694	9,041	-1,745
Comprehensive Income & Other	8,287	-1,455	-1,455	-1,472	-1,739
Total Common Equity	8,348	8,204	8,219	8,550	-2,503
Minority Interest	-41.7	-38.21	-34.89	-29.81	-30
Shareholders' Equity	8,306	8,382	8,401	8,737	-2,317
Total Liabilities & Equity	12,898	12,407	12,712	17,589	11,775
Total Debt	222.1	209.94	202.19	341.55	8,195
Net Cash (Debt)	879.1	1,353	1,928	5,175	-7,283
Net Cash Growth	-35.02%	-29.84%	-62.74%	-	-
Net Cash Per Share	14.39	22.09	31.48	84.48	-118.91
Filing Date Shares Outstanding	60.97	61.25	61.25	61.25	61.25
Total Common Shares Outstanding	60.97	61.25	61.25	61.25	61.25
Working Capital	1,782	1,763	2,365	2,142	618.81
Book Value Per Share	136.92	133.94	134.19	139.59	-40.87
Tangible Book Value	7,925	7,928	8,066	8,417	-2,643
Tangible Book Value Per Share	129.99	129.43	131.69	137.43	-43.15
Land	-	2,059	2,059	2,027	1,773
Buildings	-	3,196	3,333	3,333	3,286
Machinery	-	6,442	6,509	6,512	6,258
Construction In Progress	-	747.15	280.07	49.12	212.41

Updated Feb 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.